Pancreatic Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Cancer Type, By End User, By Region & Competition, 2021-2031F

Description

The Global Pancreatic Cancer Diagnostics Market is anticipated to expand from USD 3.01 Billion in 2025 to USD 4.59 Billion by 2031, reflecting a 7.29% CAGR, and encompasses a variety of medical tests such as biomarker assays, molecular diagnostics, biopsy techniques, and advanced imaging. Growth is primarily stimulated by the increasing worldwide prevalence of the disease, its severe mortality rates, the challenges associated with early detection, and a rising need for sophisticated tools like AI-enhanced imaging and non-invasive liquid biopsies. Highlighting the critical demand for better diagnostic solutions, the American Cancer Society projects that 67,440 people in the U.S. will be diagnosed with pancreatic cancer in 2025. However, market growth continues to be hindered by the steep costs and restricted availability of these cutting-edge technologies in certain areas, which often postpones essential patient treatment.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 3.01 Billion
Market Size 2031	USD 4.59 Billion
CAGR 2026-2031	7.29%
Fastest Growing Segment	Blood Tests
Largest Market	North America

Market Driver

A major catalyst for the expansion of the diagnostics market is the increasing global rate of pancreatic cancer, which drives the need for more accessible and efficient diagnostic instruments to catch the disease early and enhance patient prognosis. The continuous rise in cases emphasizes the critical need to identify this highly fatal cancer at more manageable stages, as noted in a January 2026 report by the Lustgarten Foundation citing the American Cancer Society, which highlighted a roughly 1% annual incidence increase since the 1990s. Simultaneously, breakthroughs in diagnostic methods, including artificial intelligence, advanced imaging, and liquid biopsies, are profoundly shaping the market by providing more accurate and less invasive staging and detection options. Collaborative efforts and funding are further accelerating this progress, exemplified by NVIDIA's August 2025 partnership with 12 global institutions to build a comprehensive pancreatic CT dataset, and AIM ImmunoTech's April 2026 rights offering that secured around $1.8 million for metastatic pancreatic cancer research.

Market Challenge

The expansion of the Global Pancreatic Cancer Diagnostics Market is significantly hindered by the high costs and limited availability of cutting-edge diagnostic tools. The substantial financial investment needed to purchase and upkeep sophisticated imaging systems, molecular platforms, and complex biomarker assays limits their integration, especially within budget-restricted healthcare networks and developing regions, thereby reducing testing volumes and slowing overall market progress. Additionally, this lack of widespread access to specialized technologies directly compromises patient outcomes by delaying crucial diagnoses. The Lustgarten Foundation, referencing the American Cancer Society's 2026 report, noted that a mere 17% of patients receive a diagnosis at a localized, highly treatable stage, underscoring a major shortfall in the application of advanced diagnostic resources as financial barriers and unequal access continue to restrict the market's reach and growth potential.

Market Trends

The Global pancreatic cancer diagnostics market is being heavily shaped by next-generation sequencing and advanced molecular profiling, which provide a profound understanding of tumor biology to help tailor personalized treatment plans. The growing accessibility and expanding reimbursement options for these sophisticated tests are encouraging broader clinical use, as seen in January 2026 when Illumina's FDA-approved TruSight test secured CMS reimbursement at $2,989.55, smoothing the path for Medicare patients and boosting market integration. Concurrently, the rise of multi-cancer early detection systems represents a crucial shift toward proactive screening, allowing for the identification of pancreatic and other cancers in individuals without symptoms. Innovations like Guardant Health's Shield blood test, which achieved a 68% sensitivity rate for pancreatic cancer in a June 2025 study and earned FDA Breakthrough Device status, are vital for expanding the diagnostic market and improving early detection for this notoriously late-diagnosed disease.

Key Market Players

Siemens Healthineers AG
Myriad Genetics, Inc.
Pfizer, Inc
Novartis AG
AstraZeneca plc
Immunovia AB
Laboratory Corporation of America Holdings
Abbott Laboratories
Agilent Technologies, Inc.
Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pancreatic Cancer Diagnostics Market, By Test Type {Diagnostic Imaging Tests

CT scan
MRI
Ultrasound
Others

Pancreatic Cancer Diagnostics Market, By Cancer Type

Exocrine
Adenocarcinoma
Squamous Cell Carcinoma
Colloid Carcinoma
Others

Pancreatic Cancer Diagnostics Market, By End User

Hospitals & Clinics
Diagnostic Centers
Others

Pancreatic Cancer Diagnostics Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Diagnostics Market.

Available Customizations:

Global Pancreatic Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pancreatic Cancer Diagnostics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Test Type {Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others)
- 5.2.2. By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others)
- 5.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Pancreatic Cancer Diagnostics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Test Type {Diagnostic Imaging Tests
- 6.2.2. By Cancer Type
- 6.2.3. By End User
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Pancreatic Cancer Diagnostics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Test Type {Diagnostic Imaging Tests
    - 6.3.1.2.2. By Cancer Type
    - 6.3.1.2.3. By End User
- 6.3.2. Canada Pancreatic Cancer Diagnostics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Test Type {Diagnostic Imaging Tests
    - 6.3.2.2.2. By Cancer Type
    - 6.3.2.2.3. By End User
- 6.3.3. Mexico Pancreatic Cancer Diagnostics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Test Type {Diagnostic Imaging Tests
    - 6.3.3.2.2. By Cancer Type
    - 6.3.3.2.3. By End User

7. Europe Pancreatic Cancer Diagnostics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Test Type {Diagnostic Imaging Tests
- 7.2.2. By Cancer Type
- 7.2.3. By End User
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Pancreatic Cancer Diagnostics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Test Type {Diagnostic Imaging Tests
    - 7.3.1.2.2. By Cancer Type
    - 7.3.1.2.3. By End User
- 7.3.2. France Pancreatic Cancer Diagnostics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Test Type {Diagnostic Imaging Tests
    - 7.3.2.2.2. By Cancer Type
    - 7.3.2.2.3. By End User
- 7.3.3. United Kingdom Pancreatic Cancer Diagnostics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Test Type {Diagnostic Imaging Tests
    - 7.3.3.2.2. By Cancer Type
    - 7.3.3.2.3. By End User
- 7.3.4. Italy Pancreatic Cancer Diagnostics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Test Type {Diagnostic Imaging Tests
    - 7.3.4.2.2. By Cancer Type
    - 7.3.4.2.3. By End User
- 7.3.5. Spain Pancreatic Cancer Diagnostics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Test Type {Diagnostic Imaging Tests
    - 7.3.5.2.2. By Cancer Type
    - 7.3.5.2.3. By End User

8. Asia Pacific Pancreatic Cancer Diagnostics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Test Type {Diagnostic Imaging Tests
- 8.2.2. By Cancer Type
- 8.2.3. By End User
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Pancreatic Cancer Diagnostics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Test Type {Diagnostic Imaging Tests
    - 8.3.1.2.2. By Cancer Type
    - 8.3.1.2.3. By End User
- 8.3.2. India Pancreatic Cancer Diagnostics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Test Type {Diagnostic Imaging Tests
    - 8.3.2.2.2. By Cancer Type
    - 8.3.2.2.3. By End User
- 8.3.3. Japan Pancreatic Cancer Diagnostics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Test Type {Diagnostic Imaging Tests
    - 8.3.3.2.2. By Cancer Type
    - 8.3.3.2.3. By End User
- 8.3.4. South Korea Pancreatic Cancer Diagnostics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Test Type {Diagnostic Imaging Tests
    - 8.3.4.2.2. By Cancer Type
    - 8.3.4.2.3. By End User
- 8.3.5. Australia Pancreatic Cancer Diagnostics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Test Type {Diagnostic Imaging Tests
    - 8.3.5.2.2. By Cancer Type
    - 8.3.5.2.3. By End User

9. Middle East & Africa Pancreatic Cancer Diagnostics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Test Type {Diagnostic Imaging Tests
- 9.2.2. By Cancer Type
- 9.2.3. By End User
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Pancreatic Cancer Diagnostics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Test Type {Diagnostic Imaging Tests
    - 9.3.1.2.2. By Cancer Type
    - 9.3.1.2.3. By End User
- 9.3.2. UAE Pancreatic Cancer Diagnostics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Test Type {Diagnostic Imaging Tests
    - 9.3.2.2.2. By Cancer Type
    - 9.3.2.2.3. By End User
- 9.3.3. South Africa Pancreatic Cancer Diagnostics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Test Type {Diagnostic Imaging Tests
    - 9.3.3.2.2. By Cancer Type
    - 9.3.3.2.3. By End User

10. South America Pancreatic Cancer Diagnostics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Test Type {Diagnostic Imaging Tests
- 10.2.2. By Cancer Type
- 10.2.3. By End User
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Pancreatic Cancer Diagnostics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Test Type {Diagnostic Imaging Tests
    - 10.3.1.2.2. By Cancer Type
    - 10.3.1.2.3. By End User
- 10.3.2. Colombia Pancreatic Cancer Diagnostics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Test Type {Diagnostic Imaging Tests
    - 10.3.2.2.2. By Cancer Type
    - 10.3.2.2.3. By End User
- 10.3.3. Argentina Pancreatic Cancer Diagnostics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Test Type {Diagnostic Imaging Tests
    - 10.3.3.2.2. By Cancer Type
    - 10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Pancreatic Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Siemens Healthineers AG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Myriad Genetics, Inc.
15.3. Pfizer, Inc
15.4. Novartis AG
15.5. AstraZeneca plc
15.6. Immunovia AB
15.7. Laboratory Corporation of America Holdings
15.8. Abbott Laboratories
15.9. Agilent Technologies, Inc.
15.10. Thermo Fisher Scientific Inc.